Tarsus Pharmaceuticals
TARS | NASDAQ
$78.68
-$1.60 (-1.99%)
At close: Nov 16, 2026, 4:00 PM ET
$78.16
-$0.52 (-0.66%)
After-hours:
Nov 16, 2026, 7:30 PM ET
Tarsus Pharmaceuticals Company Profile
Company profile explainedCompany Profile
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions. Its leading investigational drug, TP-03, a novel treatment currently in Phase III trials, is being developed to address blepharitis specifically caused by Demodex mite infestations, as well as meibomian gland disease. Beyond this, Tarsus is also progressing TP-04 for rosacea and TP-05, which targets Lyme disease prevention and aims to reduce community-level malaria. A core element of its development strategy involves lotilaner, a compound utilized to tackle a variety of human diseases across diverse therapeutic areas, encompassing eye care, dermatology, and other medical fields. Established in 2016, the company maintains its headquarters in Irvine, California.
Key Executives
| Name | Position |
|---|---|
| Bobak R. Azamian | Co-Founder, President, Chief Executive Officer & Chairman |
| Jeffrey S. Farrow | Chief Financial Officer & Chief Strategy Officer |
| Seshadri Neervannan | Chief Operating Officer |
| Adrienne Kemp | Vice President of Corporate Communications |
| Bryan Wahl | General Counsel & Corporate Secretary |
| Cara Miller | Senior Vice President of Corporate Affairs |
| David Nakasone | Head of Investor Relations |
| Dianne C. Whitfield | Chief Human Resources Officer |
| Elizabeth Yeu | Chief Medical Officer |
| Matthew Rossen | Vice President of Marketing |
| Scott Youmans | Vice President of Sales |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 13, 2026 | S-3ASR | Automatic shelf registration statement of securiti... |
| Oct 13, 2026 | S-3ASR | Automatic shelf registration statement of securiti... |
| Oct 13, 2026 | 8-K/A | [Amend] Current Report |
| Sep 17, 2026 | 4 | Filing |
| Sep 17, 2026 | 4 | Filing |
| Sep 17, 2026 | 4 | Filing |
| Sep 10, 2026 | 8-K | Current Report |
| Sep 09, 2026 | 4 | Filing |
| Sep 09, 2026 | 4 | Filing |
| Sep 09, 2026 | 4 | Filing |
Tarsus Pharmaceuticals
| Country | United States |
| IPO Date | Oct 16, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 370 |
| CEO | Bobak R. Azamian |
Contact Details
15440 Laguna Canyon Road Irvine,
California 92618 United States
Stock Details
| Ticker Symbol | TARS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001819790 |
| CUSIP Number | 87650L103 |
| ISIN Number | US87650L1035 |
| SIC Code | 2836 |
Recent News
- 11 days ago / globenewswire.comTarsus to Participate in Upcoming Investor Conferences
- 13 days ago / marketbeat.comTarsus Pharmaceuticals Q3 Earnings Call Highlights
- 13 days ago / seekingalpha.comTarsus Pharmaceuticals, Inc. (TARS) Q3 2026 Earnings Call Transcript
- 13 days ago / zacks.comTarsus Pharmaceuticals, Inc. (TARS) Reports Q3 Loss, Tops Revenue Estimates
- 13 days ago / globenewswire.comTarsus Reports Third Quarter 2026 Financial Results
- 15 days ago / zacks.comHow Much Upside is Left in Tarsus Pharmaceuticals (TARS)? Wall Street Analysts Think 30.78%
- 16 days ago / seekingalpha.comMy 'Eye' Is On Tarsus Pharmaceuticals
- 18 days ago / globenewswire.comTarsus to Report Third Quarter 2026 Financial Results on Tuesday, November 3, 2026
- 20 days ago / globenewswire.comTarsus Pharmaceuticals Appoints Neera Clase as Chief Commercial Officer
- 21 days ago / zacks.comEarnings Preview: Tarsus Pharmaceuticals, Inc. (TARS) Q3 Earnings Expected to Decline
Add to Watchlist
Select watchlists to add or remove TARS